Shares of DexCom Inc. DXCM slid 1.37% to $87.53 Monday, on what proved to be an all-around mixed trading session for the ...

Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $92 from $113 and keeps an Equal Weight rating on the shares.

Continuous Glucose Monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...

Dexcom bet on the high financial ceiling that exists by integrating its glucose monitoring capabilities into the ring, ...

In a report released today, Jeff Johnson from Robert W. Baird upgraded Dexcom (DXCM – Research Report) to a Buy, with a price target of ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, ...

Dexcom's CGM and Abbott's FreeStyle Libre are ... specific health needs, and cost. Research your options and discuss them ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...

Dexcom meanwhile currently occupies around 74% of the CGM market share in the US, according to analysis by GlobalData. The diabetes company also announced its 2025 outlook at the JP Morgan 2025 ...